On October 7, CMS updated the spreadsheet. The new spreadsheet lists Oncotype at $3416, and the change was caused by Noridian entries (which were previously blank) now being filled in at $3416.
GHDX issued a press release, clipped below.
In an earlier blog, I had wondered whether CMS had miscalculated the median based on applying "median" to states rather than MACs (here). CMS continues to calculate the median of "states" but now that median is $3416, since Noridian has so many states. I still think CMS regulations point toward use median of MACs, not median of states, but it is a moot question here since both methods give the same answer now that all the Noridian states are added to CMS's spreadsheet.
October 7, 2015
CMS Increases Final Pricing Determination for Oncotype DX® Breast Cancer Test to Previously Established Rate of $3,416
"We are pleased that CMS quickly revised its final pricing determination for the Oncotype DX breast cancer test to reflect the MAC-established rate as well as the factors set forth by